Ubicom Holdings. Inc. · TSE:3937
Ubicom — FY2025 Earnings Presentation
40 slides from Ubicom's earnings presentation, May 14, 2026
Slide 1: FY2025 Full Year Financial Results
Ubicom Holdings, Inc. (Standard Market of TSE: 3937) FY2025 ended March 31, 2026 Full Year Financial Results May 14, 2026
Slide 2: Table of Contents
Table of Contents 01 Highlights of Consolidated Financial Results for FY2025 P.3 02 Overview of Consolidated Financial Results (P/L) for FY2025 P.4 03 Medical Business P.5 04 Technology Consulting Business P.16 05 Dividend Policy P.23 06 Business Forecast ＆ Performance Trends P.25 07 Appendix P.28 ©
Slide 3: Consolidated Financial Results Highlights for FY2025
Consolidated Financial Results Highlights for FY2025 FY2025 was positioned as a “structural transformation phase” focused on strengthening the future earnings base. As a result, net sales, operating income, and ordinary income declined year on year, while net income increased. Operating income exclu
Slide 4: Overview of FY2025 Full-Year Results (P/L)
Consolidated Financial Results: Overview of FY2025 Full-Year Results (P/L) Sales, operating income, and ordinary income all declined year on year, while net income increased. Operating income excluding one-off M&A-related expenses associated with growth investments exceeded the Company’s forecast* a
Slide 5: Medical Business
Medical Business 5
Slide 6: Medical Business: Overview by Segment for FY2025 Full-Year Results
Medical Business: Overview by Segment for FY2025 Full-Year Results Both revenue and operating profit reached record highs, reflecting steady, sustained growth. This was supported by the expansion of a stable subscription revenue base and the contribution from M&A-driven scale effects, leading to str
Slide 7: Medical Business Performance Trends
Medical Business Performance Trends The revenue base was steadily strengthened through the expansion of the subscription model and the advancement of M&A, resulting in growth in both revenue and operating profit. While the acquisition of ISM’s distributor business temporarily reduced profit margins,
Slide 8: AI×Subscription Model Mighty Series User Base Trend
AI×Subscription Model Mighty Series User Base Trend Due to the Work Style Reform for physicians, which came into effect in April 2024, and the impact of the medical fee revision, digital transformation (DX) investment by medical institutions has accelerated. While focusing on migrating existing user
Slide 9: Long-Term Strategy: M&A Strategy (Nationwide Distributor Acquisitions)
Long-Term Strategy: M&A Strategy (Nationwide Distributor Acquisitions) From 2025 through 2030, the Company will advance a Group direct sales model through strategic M&A initiatives aimed at maximizing the profitability of the Medical Business. Phase 2: Subsidiary Acquisition 2030 VISION Approved the
Slide 10: M&A Strategy Phase 2: Maximizing Medical Business Profitability
M&A Strategy Phase 2: Maximizing Medical Business Profitability Purpose of M&A Outline of Subsidiary (Radianceware Inc.) Company ① Acquisition of Strategic Assets name Radianceware Inc. Strengthening one-stop medical IT proposal capabilities and technological expertise, including Acquisition ratio A
Slide 11: M&A Strategy Phase 2: Maximizing Medical Business Profitability
M&A Strategy Phase 2: Maximizing Medical Business Profitability By integrating technology platforms developed through industry-academia collaboration with one-stop medical IT solution capabilities, the Company aims to establish a value-creation partnership beyond conventional business integration. T
Slide 12: M&A Strategy Phase 2: Maximizing Medical Business Profitability
M&A Strategy Phase 2: Maximizing Medical Business Profitability Radianceware Inc. Financial Performance Trend Over the Quantitative Evaluation and Investment Past Three Years Decision for This M&A （Unit：million yen) Sales 3 consecutive years of ① Comparison with Target Payback Period revenue and pro
Slide 13: Launch of New Product MightyChecker Cloud X
Launch of New Product “MightyChecker® Cloud X” N e x t - g e n e r a t i o n c l o u d - b a s e d me d i ca l c l a i ms i n s p e c t i o n s o f t w a re Launch of New Product “MightyChecker® Cloud X” (April 2026) Features of MightyChecker® Cloud X Targets Improved Operational Efficiency Migratio
Slide 14: Insurance Knowledge Platform Driving DX in the Insurance Industry
“Insurance Knowledge Platform” Driving DX in the Insurance Industry Leveraging a proprietary medical data infrastructure accumulated over 40 years and AI-based diagnostic prediction capabilities, the Company is promoting digital transformation (DX) for insurance companies. It provides a business sup
Slide 15: Medium- to Long-Term Growth Strategy for the Medical Business
Medium- to Long-Term Growth Strategy for the Medical Business We aim to achieve medium- to long-term growth through a dual-track strategy combining stable recurring organic growth with M&A-driven expansion. In the short term, we prioritize top-line growth as a strategic investment to scale revenue.
Slide 16: Technology Consulting Business
Technology Consulting Business 16
Slide 17: Technology Consulting Business: Overview by Segment for FY2025
Technology Consulting Business： Overview by Segment for FY2025 Full-Year Results (Business Performance) Promoting a shift toward a high value-added, high-productivity model by advancing AI-driven development and operational sophistication, while transforming the business model to deliver new client
Slide 18: Technology Consulting Business: Philippine Subsidiary Performing Strongly
Technology Consulting Business: Philippine Subsidiary Performing Strongly 【Factors Behind Strong Performance at the Philippine Base (Slight Revenue Decline with Profit Growth)】 • Revenue at the Philippine subsidiary consists of approximately half from projects through the Japanese parent company and
Slide 19: Establishment of an AI-driven development framework
Establishment of an AI-driven development framework (medium- to long-term strategy) As a strategic partner of IBM Japan, the Company is establishing an AI center in the Philippines ※to support the transition to a high value-added, high-productivity model centered on the enterprise AI platform watson
Slide 20: Roadmap for Building an AI-Driven Development Framework
Roadmap for Building an AI-Driven Development Framework Phased development of an AI-driven development framework leveraging IBM’s AI Q4 of FY2026 platform (watsonx) and other technologies, Implementation & progressing through 3 stages: Commercialization Phase Validation ⇒ PoC ⇒ Implementation Valida
Slide 21: Overview of AI Use Cases by Industry
Technology Consulting Business: Overview of AI Use Cases by Industry Company-wide AI adoption Test Phase Design Phase Document Generation Test Automation Requirements definition Report Creation Document Summarization support Test code creation Error Resolution Design document analysis AI Use Cases (V
Slide 22: Target Domains for Building an AI-Driven Development Framework
Target Domains for Building an AI-Driven Development Framework The generative AI market is expected to expand both in Japan and worldwide, with particularly strong demand anticipated toward 2030 in the financial, manufacturing, and energy sectors. Against this backdrop, the company positions highly
Slide 23: Dividend Policy
Dividend Policy 23
Slide 24: A dividend policy enabling shareholders to directly benefit from growth
A dividend policy enabling shareholders to directly benefit from growth 【Dividend Policies】 ① Despite missing guidance for FY2025 due to temporary impacts from growth investments and portfolio optimization, the core Medical Business continued to strengthen its earnings base, while the Technology Con
Slide 25: Business Forecast & Performance Trends
Business Forecast ＆ Performance Trends 25
Slide 26: Earnings Forecast and Financial Performance Trend
Earnings Forecast and Financial Performance Trend [Earnings Forecast] • For FY2026 forecast, we expect further expansion of the revenue base in the medical business and contributions from newly acquired subsidiaries through M&A. • The forecast incorporates higher depreciation expenses related to the
Slide 27: Earnings Forecast and Financial Performance Trend: Key Strategic Initiatives
Earnings Forecast and Financial Performance Trend 【Key Strategic Initiatives】 ① Continuous execution of M&A strategy The company will continuously promote M&A to expand its revenue base and accelerate the accumulation of recurring income. Early realization of synergies will be achieved through post-
Slide 28: Appendix
Appendix 28
Slide 29: Our Business Model: A Model for Resolving Social Issues in Japan
Our Business Model: A Model for Resolving Social Issues in Japan, A Developed Country Facing Challenges 01 Medical Business 02 Technology Consulting Business Reforming the workstyle of Against the backdrop of an ※ medical professionals anticipated shortage of 3.26 Improving the profitability Mission
Slide 30: The Tailwind created by Social issues and Political measures
The Tailwind created by Social issues and Political measures (Market environment) Increasing deficits of medical institutions and social security spending cuts: three growth opportunities arising from structural challenges Increasing deficits in The coverage rate of EMR is Business fields aligned wi
Slide 31: The flagship product of the Mighty series
The flagship product of the “Mighty” series, which leverages AI to enhance operational efficiency in healthcare institutions 【For doctors】AI-oriented EMR Diagnosis Input Support & Input Verification System for Doctors By linking with electronic medical records, the AI derives possible diagnoses ba
Slide 32: Impact of M&A Strategy Execution (KPI Changes)
Impact of M&A Strategy Execution (KPI Changes) Over the five years from 2025 to 2030, we will execute 8 to 10 M&A deals with the aim of increasing the group's direct sales ratio. ＜Factors contributing to LTV ※1 improvement＞ Content Measurement details Increase of ①Inclusion of agency profits in grou
Slide 33: Medical Business: Revenue Recognition Methods (Billing Methods)
Medical Business：Revenue Recognition Methods (Billing Methods) License revenue for the Mighty series adopts a “instalment recognition” method. With the increase in contract numbers, sales steadily accumulate on a monthly basis, achieving revenue stabilization. Furthermore, the AI × subscription mode
Slide 34: Technology Consulting Business: About AI-driven development model
Technology Consulting Business： About AI-driven development model 【Background for Adopting watsonx in AI-Driven Development Model】 Dramatic Growth Potential • AI-powered models enable the automation of development processes, significantly reducing development time. • As a result, scalable growth tha
Slide 35: A new value and differentiation strategy created by Designed Lab-type Development
A new value and differentiation strategy created by the「Designed Lab-type Development」 【 Risks and Concerns of Conventional Offshore Development 】 In the case of setting up an offshore base In case the of conventional Lab-type development Client Offshore development company Client’s base Client Lab
Slide 36: Promotion of Group Businesses Based on Social Significance
Promotion of Group Businesses Based on Social Significance Provision of solutions that are beneficial to three key areas: pressing need for workstyles Growing demand due to the reforms for medical doctors, improvement in reassessment of offshore development management of medical institutions, and DX
Slide 37: ESG: For sustainable growth of business, society, and client companies
ESG：For sustainable growth of business, society, and client companies Goals Concrete Activities Related SDGs ・To make the electric power consumed E ・To reduce CO2 emissions at the head office 100% derived from renewable energy ・Global partnership ・Investment in equipment of subsidiaries in the Phili
Slide 38: Corporate Profile
Corporate Profile ■Corporate name: Ubicom Holdings, Inc. (Standard Market of TSE: 3937) ■Strategic markets: healthcare, finance, public services, automobiles, manufacturing, robotics, etc. ■Business description: Technology Consulting Business In order to solve the problem of shortage of IT engineers
Slide 39: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements The materials and information provided in this announcement include forward-looking statements based on our current estimates and expectations at this point of time. Such forward-looking statements are subject to various risks and uncertaintie
Slide 40: Holdings, Inc.
Holdings, Inc. = fe) Q Q =) 40